NASDAQ
THTX

Theratechnologies Inc.

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Theratechnologies Inc. Stock Price

Vitals

Today's Low:
$2.18
Today's High:
$3.29
Open Price:
$2.9
52W Low:
$0.9
52W High:
$11.06
Prev. Close:
$2.89
Volume:
686332

Company Statistics

Market Cap.:
$22.75 million
Book Value:
-1.716
Revenue TTM:
$79.69 million
Operating Margin TTM:
-22.87%
Gross Profit TTM:
$56.22 million
Profit Margin:
-45.09%
Return on Assets TTM:
-13.88%
Return on Equity TTM:
-1116.86%

Company Profile

Theratechnologies Inc. had its IPO on 2016-01-04 under the ticker symbol THTX.

The company operates in the Healthcare sector and Biotechnology industry. Theratechnologies Inc. has a staff strength of 144 employees.

Stock update

Shares of Theratechnologies Inc. opened at $2.9 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.18 - $3.29, and closed at $2.43.

This is a -15.92% slip from the previous day's closing price.

A total volume of 686,332 shares were traded at the close of the day’s session.

In the last one week, shares of Theratechnologies Inc. have increased by +158.51%.

Theratechnologies Inc.'s Key Ratios

Theratechnologies Inc. has a market cap of $22.75 million, indicating a price to book ratio of 20.1291 and a price to sales ratio of 1.2032.

In the last 12-months Theratechnologies Inc.’s revenue was $79.69 million with a gross profit of $56.22 million and an EBITDA of $-14952000. The EBITDA ratio measures Theratechnologies Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Theratechnologies Inc.’s operating margin was -22.87% while its return on assets stood at -13.88% with a return of equity of -1116.86%.

In Q1.6666666666667, Theratechnologies Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a negative 8.9%.

Theratechnologies Inc.’s PE and PEG Ratio

Forward PE
55.8659
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.45 per share while it has a forward price to earnings multiple of 55.8659 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Theratechnologies Inc.’s profitability.

Theratechnologies Inc. stock is trading at a EV to sales ratio of 1.5867 and a EV to EBITDA ratio of -4.1557. Its price to sales ratio in the trailing 12-months stood at 1.2032.

Theratechnologies Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$68.73 million
Total Liabilities
$71.32 million
Operating Cash Flow
$0
Capital Expenditure
$81000
Dividend Payout Ratio
0%

Theratechnologies Inc. ended 2024 with $68.73 million in total assets and $0 in total liabilities. Its intangible assets were valued at $68.73 million while shareholder equity stood at $-41531000.00.

Theratechnologies Inc. ended 2024 with $0 in deferred long-term liabilities, $71.32 million in other current liabilities, 338751000.00 in common stock, $-403105000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $16.96 million and cash and short-term investments were $25.37 million. The company’s total short-term debt was $27,770,000 while long-term debt stood at $38.11 million.

Theratechnologies Inc.’s total current assets stands at $51.13 million while long-term investments were $0 and short-term investments were $8.41 million. Its net receivables were $13.60 million compared to accounts payable of $33.61 million and inventory worth $9.16 million.

In 2024, Theratechnologies Inc.'s operating cash flow was $0 while its capital expenditure stood at $81000.

Comparatively, Theratechnologies Inc. paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.43
52-Week High
$11.06
52-Week Low
$0.9
Analyst Target Price
$17.75

Theratechnologies Inc. stock is currently trading at $2.43 per share. It touched a 52-week high of $11.06 and a 52-week low of $11.06. Analysts tracking the stock have a 12-month average target price of $17.75.

Its 50-day moving average was $2.14 and 200-day moving average was $3.49 The short ratio stood at 0.45 indicating a short percent outstanding of 0%.

Around 1047.3% of the company’s stock are held by insiders while 2859.8% are held by institutions.

Frequently Asked Questions About Theratechnologies Inc.

The stock symbol (also called stock or share ticker) of Theratechnologies Inc. is THTX

The IPO of Theratechnologies Inc. took place on 2016-01-04

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$4322.3
-224.35
-4.93%
$372.05
-29.35
-7.31%
Tarmat Limited (532869)
$67.66
-4.18
-5.82%
$10.9
-0.44
-3.88%
$0.84
0.02
+2.44%
$3.09
0.02
+0.65%
$3.8
0.08
+2.15%
Tsumura & Co (TSMRF)
$21.95
1.52
+7.44%
$279.55
-5.7
-2%
$2.41
-0.12
-4.74%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Address

2015 Peel Street, Montreal, QC, Canada, H3A 1T8